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Alzheimer’s disease (AD) is a chronic, progressive, brain disorder that affects at least 5.3
million Americans at an estimated cost of $148 billion, figures that are expected to rise
steeply in coming years. Despite decades of research, there is still no cure for AD, and
effective therapies for preventing or slowing progression of cognitive decline in at-risk pop-
ulations remain elusive. Although the etiology of AD remains uncertain, chronic stress,
sleep deficits, and mood disturbance, conditions common in those with cognitive impair-
ment, have been prospectively linked to the development and progression of both chronic
illness and memory loss and are significant predictors of AD.Therapies such as meditation
that specifically target these risk factors may thus hold promise for slowing and possibly
preventing cognitive decline in those at risk. In this study, we briefly review the existing
evidence regarding the potential utility of meditation as a therapeutic intervention for those
with and at risk for AD, discuss possible mechanisms underlying the observed benefits of
meditation, and outline directions for future research.
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Alzheimer’s disease (AD), the most common form of dementia, is
a chronic, progressive, brain disorder resulting in a loss of mem-
ory, reasoning, language skills, and the ability to care for one’s self
(1). AD is the seventh leading cause of death in the US (2), affect-
ing 5.2 million Americans at an estimated cost of $214 billion,
figures that are expected to increase dramatically in the coming
years (3, 4). AD affects quality of life for both the patient and
the caregiver in profound ways. Many individuals with cogni-
tive impairment become unable to engage in once loved activities
that gave them a sense of purpose or pleasure (5). Behavioral and
social skills may also deteriorate, which in turn, further increase
risk for poor mental and physical health outcomes (6, 7). For
example, neuropsychiatric symptoms are common in adults with
AD (8–10), with up to 64% of AD patients experiencing dis-
turbed sleep (11) and up to 87% suffering depressive symptoms
(12, 13).
In most patients, AD develops slowly, often preceded years
earlier by perceived and/or objective cognitive decline, offering
a potential window for therapeutic intervention. First defined in
the late 1990s and now widely recognized, mild cognitive impair-
ment (MCI) is generally considered a transition phase between
healthy cognitive aging and dementia (14, 15). Risk of progression
to AD in those with MCI is very high, with an estimated 5–15%
of those with MCI converting to AD each year (14–16), and up to
50% or more eventually progressing to AD (15). More recently, an
even earlier harbinger of cognitive impairment, subjective cog-
nitive impairment (SCI), has been associated with accelerated
decline in cognitive function, an up to 4.5-fold increased risk
for progression to MCI, and an approximately threefold elevated
likelihood of developing AD (17–20). The annual conversion rate
from SCI to MCI or dementia in otherwise healthy individuals
has been estimated to be 7–10% (20, 21). While cognitive per-
formance is only modestly reduced in those with MCI, and is
in the normal range in those with SCI (22), recent research has
shown cerebral spinal fluid markers of AD to be more common
in adults with SCI and MCI, and to be associated with cogni-
tive decline in those with MCI (23). In addition, prevalence of
neuropsychiatric impairment is high in both these at-risk popula-
tions (8–10, 22), and, as discussed in more detail below, cognitive
function appears strongly related, in a bidirectional manner, to
anxiety, depression, and sleep disturbance (22, 24, 25). Up to
62% of MCI patients experience sleep disturbance (25, 26) and
up to 83% suffer depressive symptoms (13), rates similar to those
reported in AD (11, 12, 26). Similarly, adults with subjective mem-
ory complaints are significantly more likely to report symptoms
of depression (19, 27) and anxiety (19). As detailed below, these
mood and sleep disturbances lead, in turn, to accelerated cognitive
decline and deterioration of both physical and mental health (12,
25, 28–31).
CHRONIC STRESS, SLEEP IMPAIRMENT, MOOD
DISTURBANCE, AND COGNITIVE DECLINE: A VICIOUS CYCLE
Chronic stress can contribute to a vicious cycle that may not only
have deleterious effects on health and cognitive function (32),
but ultimately increase risk for institutionalization (29, 30). The
chronic stress that often characterizes the lives of those with cog-
nitive impairment, as well as their caregivers, has been linked to
adverse changes in sleep (30), mood (33, 34), and immunological
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function (33, 35), and elevated risk for metabolic syndrome,
cardiovascular disease (CVD), and mortality (36, 37). Chronic
psychological stress can have profound effects on memory and
behavior in persons both with and without cognitive impair-
ment, and has been prospectively linked to increased risk for
incident MCI and dementia in older adults, and to accelerated
cognitive decline (38–40). Chronic stress leads to deleterious neu-
roendocrine and associated inflammatory changes, to suppression
of IGF-1 and other neuroprotective factors, and to impaired synap-
tic plasticity, suppressed neurogenesis, reduced neuronal survival,
and other adverse morphological and functional changes in the
hippocampus, prefrontal cortex, and other brain structures; all
these changes can profoundly affect mood, sleep, memory, and
learning (41–45). A large body of experimental, clinical, and epi-
demiological research has also implicated chronic stress and asso-
ciated sympathoadrenal activation in the etiology of hypertension,
obesity, dyslipidemia, and other components of the metabolic syn-
drome, and in the development and progression of CVD, type 2
diabetes, depression, and related chronic disorders (41, 46). These
disorders have, in turn, been shown to predict cognitive dysfunc-
tion, and to increase risk for the development and progression
of AD (47–54). Autonomic and hypothalamic pituitary adrenal
(HPA) axis dysfunction has also been linked directly to cognitive
decline, and to adverse changes in brain structure and function.
For example, HPA axis activation, manifested by elevated corti-
sol levels, has been associated with hippocampal volume loss and
memory impairment in non-demented elders (41, 55).
As noted above, depression and other mood disorders are com-
mon in those with and at risk for AD, including adults with MCI
and SCI (12, 13, 28, 56). Depressive symptoms and other dis-
tressful states have also been linked to significantly increased risk
for diabetes, CVD, stroke, and the metabolic syndrome (57–59),
and are a significant contributor to the profound reductions in
quality of life reported by those with cognitive impairment (12,
31). Anxiety and depressive symptoms are also significant predic-
tors of cognitive decline and incident cognitive impairment (60,
61). Moreover, in those with MCI, behavioral and psychological
symptoms, including anxiety, depression, irritability, and apathy,
are strong predictors of progression to AD (28, 62). In addition,
mood disturbance can contribute not only to impairment of mem-
ory, but also to sleep disturbance, HPA axis dysregulation, and
autonomic dysfunction and related pro-inflammatory changes,
thus helping to promote a vicious cycle of adverse physiologic,
neuroendocrine, and psychosocial changes that foster the develop-
ment and progression of AD, CVD, and related chronic conditions
(41, 63, 64).
Sleep disruption, also common in cognitively impaired adults
(26), likewise has negative effects on health, functioning, and qual-
ity of life, and is a major reason for institutionalization (25, 29, 30,
65, 66). Sleep deficits are known to impair cognitive function in
healthy populations (67, 68), to accelerate cognitive decline (29,
30), and to predict incident MCI and dementia (25). In addition,
sleep disturbances have been strongly associated, in a bidirectional
manner, with mood disorders (69) and autonomic dysfunction
(70, 71), and can promote glucose intolerance, pro-inflammatory
changes, dyslipidemia, obesity, and hypertension (70, 72, 73). Sleep
impairment has likewise been linked to increased risk for incident
type 2 diabetes and for CVD morbidity and mortality (41, 72–74),
disorders that have, in turn, been significantly and prospectively
linked to AD (75–78). The association of impaired sleep to chronic
illness and related risk factors appears strongly reciprocal (72, 79).
ALZHEIMER’S DISEASE AND COGNITIVE IMPAIRMENT: NEED
FOR NEW PREVENTION AND TREATMENT STRATEGIES
Despite decades of research, there is still no cure for AD. While
a number of lifestyle factors have been linked to the subse-
quent development of this devastating disorder, effective therapies
for preventing or slowing progression of AD in at-risk popula-
tions remain elusive (80), and there are no approved treatments
for MCI or age-associated cognitive decline (22, 81). Given the
high prevalence of chronic stress, sleep disturbance, and mood
impairment in those with or at risk for cognitive impairment,
the deleterious impact of these and related factors on health and
cognitive function, interventions that specifically address these
risk factors may hold promise not only for enhancing health and
well-being, but also for slowing and possibly preventing cogni-
tive decline in those at risk for AD. Of particular interest in this
regard is meditation, an ancient mind–body practice that is gain-
ing increasing favor throughout the western industrialized world
as a means of reducing stress and improving both mental and
physical well-being (82).
MEDITATION: HEALTH EFFECTS AND THERAPEUTIC PROMISE
Meditation has been broadly defined as “an intentional and self-
regulated focusing of attention, whose purpose is to relax and
calm the mind and body” (83). The studies included in this
mini-review encompass a wide variety of meditative techniques,
including mantra, mindfulness, and Kundalini meditation prac-
tices, among others. As indicated in recent systematic reviews
by our group and other investigators, and by the growing body
of original research on the health effects of meditation, there is
mounting evidence that even brief meditative practices (5 days–8
weeks) may improve neuropsychological, metabolic, and clinical
profiles in a range of populations (82, 84–87). For example, stud-
ies have shown meditation to reduce perceived stress (85, 88–90),
anxiety (85, 88–91), and depressive symptoms (89–92), enhance
quality of life (87, 92), decrease sleep disturbance (90, 93), improve
several domains of cognition (90, 94, 95), reduce sympathetic acti-
vation and enhance cardiovagal tone (96–99), both acutely and
long term in clinical as well as non-clinical populations (84, 100).
A growing body of research also suggests that meditation promotes
beneficial changes in CNS dopaminergic and other neurochemi-
cal systems (101, 102), and increases blood flow, oxygen delivery,
and glucose utilization in specific regions of the brain associ-
ated with mood elevation, memory, and attentional processing,
including the hippocampus, prefrontal cortex, and anterior cin-
gulate gyrus (91, 95, 103–106). Long-term meditation practice
has also been associated with cortical thickening and increased
gray matter volume in brain regions involved in attentional per-
formance, sensory processing, and interoception (103, 107, 108),
apparently offsetting typical age-related cortical thinning and gray
matter loss (108). In addition, recent research suggests that medi-
tation programs can enhance immune response (109) and clinical
outcomes (82, 85), and reduce blood pressure (85, 90, 100, 110),
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insulin resistance and glucose intolerance (97,111),oxidative stress
(84, 112), inflammation (93), and other related risk indices (84,
85). While research in cognitively impaired populations remains
limited, findings from previous observational studies (113, 114)
and two recent small clinical trials (90, 91, 95, 105) suggest that
meditation practice may reduce stress, anxiety, depression, and
blood pressure; improve cognition; promote beneficial changes in
brain structure and function; and improve health outcomes in
adults with memory disorders.
In addition to its many reported health benefits, meditation car-
ries numerous practical advantages as a therapeutic intervention
and health promotion method. It is a simple, economical, non-
invasive therapy that is easy to learn and can be practiced even by
very elderly, ill, or disabled individuals, including those suffering
from cognitive impairment (82, 90, 95, 115). Requiring no special
equipment and little in the way of professional personnel, med-
itation is a practice that is relatively easy to maintain at no cost,
with several studies indicating excellent long-term adherence (84,
116, 117). Meditation practice typically brings immediate posi-
tive benefits, including feelings of relaxation and tranquility, and
even short-term (5 day–6 week) meditation programs have been
shown to result in significant improvement in mood, sleep, and
other distressful symptoms (82, 84, 97, 110), helping to encour-
age continued practice. Several studies indicate that meditation
programs may also reduce health care costs in both clinical and
non-clinical populations (82, 118).
POTENTIAL UNDERLYING MECHANISMS
Although the mechanisms underlying the putative beneficial
effects of meditation on cognitive, psychological, and physical
health are not yet well understood, the observed changes likely
occur through at least four pathways (41, 46, 84, 85, 101, 119).
First, by reducing activation and reactivity of the sympathoadrenal
system and the HPA axis and promoting feelings of well-being,
meditation may alleviate the effects of stress, enhance sleep and
mood, and foster multiple positive downstream effects on cogni-
tion, neuroendocrine status, neurological and metabolic function
and related inflammatory responses (Figure 1, pathway 1). Sec-
ond, meditation may enhance parasympathetic output, possibly
via direct vagal stimulation, and thereby shift the autonomic
nervous system balance from primarily sympathetic to parasym-
pathetic, leading to positive changes in cardiovagal function, in
mood, sleep, and energy state, and in related neuroendocrine,
metabolic, and inflammatory responses, in turn, reducing risk for
depression and cognitive decline (Figure 1, pathway 2). Third,
findings of recent neuroimaging and neurophysiological studies
(98, 106, 120) suggest that meditation, by selectively activating
specific neurochemical systems and brain structures associated
with positive mood, attention, and memory, may likewise pro-
mote beneficial changes in sympathetic/parasympathetic balance,
in neurological structure and function, in affect and memory, and
in related metabolic and inflammatory responses (Figure 1, path-
way 3). Finally, findings of a recent study in dementia caregivers
(121) suggest that meditation may also, by directly or indirectly
stimulating increased telomerase activity, help promote telomere
maintenance and buffer the effects of stress-induced cellular aging,
thereby helping to preserve immune function and possibly reduce
neuronal loss and other degenerative changes associated with aging
and cognitive decline (122, 123). As discussed below, reductions in
telomerase activity and telomere length have been linked to stress,
depression, sleep loss, and cognitive impairment (99, 124–135)
and shown to predict cognitive decline in both clinical and non-
clinical populations (136, 137). Likewise, recent research in healthy
adults (138–140), lonely older adults (141), and depressed demen-
tia caregivers (142, 143) suggest that meditation may also buffer or
reverse multiple stress-related changes in specific gene expression
pathways implicated in the development and progression of AD,
including those regulating oxidative stress, inflammation, cellular
aging, and other factors contributing to impaired brain structure
and function, and ultimately, to cognitive decline (144–150).
Pathway
1
Pathway 
2
Pathways
3/4
Improved 
Metabolic proﬁle
↓ Oxida"ve stress
↑ Glucose tolerance
↓ Dyslipidemia
↓ Obesity ↓Risk 
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Decline   
and AD 
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↑ Parasympathe"c 
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FIGURE 1 | Possible pathways by which meditation may improve health outcomes in adults with cognitive impairment.
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TELOMERES, INFLAMMATION, COGNITIVE DECLINE, AND CHRONIC
STRESS: POSSIBLE BENEFITS OF MEDITATION
An emerging body of literature suggests that both inflamma-
tion and telomere maintenance may be important factors in the
pathogenesis of AD. Telomeres are DNA–protein complexes that
protect the ends of chromosomes,and are essential for maintaining
chromosomal integrity during replication (127, 151). The cellular
enzyme telomerase acts to repair and replace the genetic telomeric
material lost, helping to counteract the telomere shortening that
occurs with age. There is growing evidence linking both shorter
telomere length and lower telomerase activity with reduced sur-
vival and several age-related diseases (127, 151, 152), including
AD (152–156) and suggesting that these telomeric alterations may
mediate the degenerative changes associated with these conditions
(131, 151, 157). Telomere shortening has been linked to cogni-
tive impairment in several non-clinical populations (124–126)
and shown in prospective studies to predict cognitive decline in
post-stroke patients (136) and older community-dwelling women
(137). Moreover, recent studies suggest that several lifestyle and
environmental factors are important determinants of both telom-
ere length and telomerase activity (127, 131, 152). Notably, these
factors include chronic stress, depression, and impaired sleep, now
emerging as powerful predictors of accelerated telomere shorten-
ing and reduced telomerase activity (99, 127–135). As indicated
above, these deleterious changes may be buffered by meditative
practices (99, 121, 158).
Telomere degradation may also be accelerated by chronic
inflammation (156, 159, 160) which is, in turn, thought to be
an important mechanism underlying cognitive decline and the
pathogenesis of AD (54). Systemic inflammatory markers, includ-
ing IL-6, TNF-alpha, and hsCRP, have been linked to loss of
cerebral volume, and large population-based studies have con-
sistently shown high blood levels of these inflammatory indices,
to predict cognitive decline (54). Elevated inflammatory markers
are also strongly associated, in a bidirectional manner, to chronic
psychological stress, mood disturbance, sleep loss, and other dis-
tressful states (41, 72, 161–165). Emerging evidence suggests that
meditative practices can not only reduce stress, improve sleep,
and enhance mood, but may also decrease indices of systemic
inflammation (121, 166, 167).
GENOMIC CHANGES IN COGNITIVE IMPAIRMENT, STRESS, AND
POTENTIAL BENEFITS OF MEDITATION
Genomic changes characterizing the inception and progression of
AD is an active area of investigation (168–170). To date, over 180
genes distributed across the human genome have been directly or
indirectly implicated in the pathogenesis of AD (168). Transcrip-
tional profiling of blood mononuclear cells by microarray in those
with AD have identified 19 upregulated and 136 downregulated
genes (170, 171). While gene expression profiling in those with
or at risk for AD is an emerging and still rapidly developing field
of inquiry, recent studies suggest that multiple changes in gene
expression may be important in AD progression (145, 147–150).
These include alterations related to pro-inflammatory pathways
(145), immune function (146), synaptic function (150), and regu-
lation of apoptosis (146), oxidative stress (144) and other pathways
(147, 148, 171); several of these changes have been linked to
chronic psychological stress (139, 140, 144). Exploratory research
in depressed dementia caregivers (142) and lonely older adults
(141), as well as in healthy adults (138–140), suggests that the prac-
tice of meditation may lead to multiple beneficial changes in gene
expression and may buffer or reverse adverse stress-related changes
in transcriptional profiles. These include favorable alterations in
several pathways linked to cognitive impairment, including those
regulating cellular metabolism and aging, oxidative stress, immune
function, inflammation, DNA repair, cell-cycle control, and apop-
tosis (138–143). However, while these preliminary findings sug-
gest that meditative practices may help prevent, mitigate, or even
reverse specific genomic changes implicated in cognitive decline,
studies regarding the effects of meditation or other mind-body
therapies on gene expression profiles in adults with memory loss
are lacking.
SUMMARY
In brief, meditation may offer considerable promise as a safe and
cost-effective intervention for reducing stress and for improving
cognition, mood, sleep, and related outcomes in adults with or
at risk for cognitive impairment. However, despite the appar-
ent therapeutic potential of meditation for these populations,
research remains sparse, and interpretation of existing studies
is limited by small sample sizes, selection bias, and/or lack of
appropriate control groups. Clearly, larger, rigorous randomized
controlled trials are needed to establish the efficacy of medita-
tion for improving cognitive function, stress, mood, sleep and
related neuropsychosocial and physiological outcomes in adults
with cognitive impairment, and to examine the long-term effects
of meditation on cognitive decline and on the inception and pro-
gression of AD. Also needed are high-quality studies to assess the
potential cost-effectiveness of meditation as a therapeutic inter-
vention for those with or at risk for cognitive impairment, and to
investigate potential underlying mechanisms, including changes
in inflammatory markers, brain structure and function, cellular
aging, and gene expression. If future studies show meditation to
be effective in reducing stress and improving cognition and related
outcomes in adults at risk for AD, it may offer a novel, safe, and
low-cost approach to preventing or slowing cognitive decline in
this population, and ultimately help reduce the significant health
and economic burden associated with AD.
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